Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
5155(c) 5166(c) 5176(c) 5175(c) 5162(c) Last
2 029 967 2 113 688 1 601 726 2 555 117 1 718 840 Volume
+0.55% +0.21% +0.19% -0.02% -0.25% Change
More quotes
Financials ($)
Sales 2017 21 558 M
EBIT 2017 5 959 M
Net income 2017 2 524 M
Debt 2017 12 193 M
Yield 2017 4,00%
Sales 2018 22 023 M
EBIT 2018 5 985 M
Net income 2018 3 002 M
Debt 2018 13 080 M
Yield 2018 4,04%
P/E ratio 2017 30,76
P/E ratio 2018 25,99
EV / Sales2017 4,55x
EV / Sales2018 4,50x
Capitalization 85 977 M
More Financials
Company
AstraZeneca Plc is a holding company, which engages in the research, development and manufacture of pharmaceutical products.The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.Its... 
Sector
Pharmaceuticals
Calendar
11/09 | 08:00amEarnings Release
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
10/20 ASTRAZENECA : lobbies for personalized asthma care with new visual snapshot tool
10/20 ASTRAZENECA : US FDA accepts regulatory submission for Lynparza in metastatic br..
10/19 ASTRAZENECA : Researchers from AstraZeneca Report on Findings in Disease Progres..
10/19 ASTRAZENECA : TAGRISSO® osimertinib Granted Breakthrough Therapy Designation by ..
10/19 ASTRAZENECA : Findings on Antibiotics Reported by Investigators at AstraZeneca (..
10/19 ASTRAZENECA : Reports Outline Obesity, Fitness and Wellness Study Results from A..
10/19 ASTRAZENECA : US FDA accepts supplemental Biologics License Application for IMFI..
10/18 ASTRAZENECA : Announces New Data Showing US Preterm Infants at Significantly Gre..
10/18 ASTRAZENECA : US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 FDA ACCEPTS ASTRAZENECA PLC (ADR)(NY : AZN) Imfinzi’s Supplemental Biologi..
More news
Sector news : Pharmaceuticals - NEC
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ASTRAZENECA 
ASTRAZENECA - 2016
A rally could take place
BUY
More Strategies
Latest Tweets
12:19pGreat companies model commitment & encourage innovation. on AstraZeneca/..
3
10/20AstraZeneca plc given GBX 4,700 PT by Morgan Stanley. neutral rating.  
10/20., EVP of our IMED Biotech Unit, on what distinguishes AstraZeneca & as ..
3
10/20Roivant bags AstraZeneca drug in latest bid  
10/20AstraZeneca EVP: Brexit is hindering our hiring: Fierce Biotech  
More tweets
Qtime:118
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/18 FDA accepts Myriad Genetics' application for companion diagnostic test for As..
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 66,4 $
Spread / Average Target -2,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA16.62%85 977
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223